Skip to main content
Premium Trial:

Request an Annual Quote

Bruker to Pocket at Least $14.7M in Stock Offering

NEW YORK (GenomeWeb News) — Bruker BioSciences today said it expects to pocket at least $14.7 million after issuing a stock offering.
The company said proceeds from the sale may be used for general purposes, repaying debts, and potential acquisitions. 
The company said it expects to sell 10.4 million shares at $7.10 apiece. Bruker said it expects selling stockholders to earn roughly $54.9 million. 
Bruker said 2.2 million shares will be sold through the company and 8.2 million will be offered through four stockholders. 
Bruker said it also has offered underwriters an option to buy an additional 330,000 shares, and selling stockholders have offered an option to buy 1.23 million shares.
This additional offering should bring in an extra $2.2 million for the company and $8.3 million for the stockholders.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.